Research square · 2026
First-Day Glycemic Exposure and 28-Day Mortality in the ICU: A Multicohort Study.
СтатьяПрепринтНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Odera Joab O, Blas Achic Betsabe G, Cha Julie, Montgomery Aisha, Ojwang Alice A, Masenga Sepiso, Odera Elizabeth O, Osazuwa-Peters Nosayaba, Yalamanchi Ananya, Han David, Hinton Antentor O
Аннотация
IMPORTANCE: Early glycemic exposure in the ICU is common and clinically modifiable, yet bedside assessment often relies on single glucose values rather than exposure-aware metrics. Interpretable, first-day prediction may support individualized glycemic targets and early intervention.
OBJECTIVE: To examine the association between first-day time-weighted average glucose (TWAG) and 28-day mortality, and to evaluate GlucoSurvAI, an interpretable ensemble model for first-day risk stratification.
DESIGN SETTING AND PARTICIPANTS: Retrospective cohort study using electornic health records from 13 U.S. hospitals. Among 18,868 adult ICU encounters, 8,048 patients from 7 U.S. hospitals met inclusion criteria (≥1 glucose value and hospital length of stay ≥24 hours).
EXPOSURES: First-day glycemic exposure summarized as TWAG, categorized as <100, 100-139 (reference), 140-179, and ≥180 mg/dL. Prespecified covariates included diabetes/prediabetes, first-day insulin and glucose, corticosteroids, vasopressors, shock, cancer, glucose-monitoring intensity, and clinical site.
MAIN OUTCOME AND MEASURES: Primary outcome: 28-day all-cause mortality. Associations were estimated with multivariable Cox models (adjusted hazard ratios [aHRs], 95% CIs). GlucoSurvAI performance was assessed using Area Under the Receiver Operating Characteristic (AUROC) and Brier score; SHapley Additive exPlanations (SHAP) provided 28-day interpretability.
RESULTS: Of 8,048 patients, most were euglycemic (70-180 mg/dL) on day 1, although hyperglycemic excursions were frequent. Higher TWAG was associated with higher 28-day mortality: 140-179 mg/dL aHR 1.42 (95% CI, 1.25-1.62); ≥180 mg/dL aHR 1.41 (95% CI, 1.17-1.69). TWAG <100 mg/dL showed a nonsignificant trend toward higher survival. GlucoSurvAI achieved AUROC 0.967 (±0.008) with a low Brier score (~0.026). Adjusted SHAP analyses paralleled Cox results, identifying 100-139 mg/dLas the exposure range associated with decreased mortality, with risk increasing ≥140 mg/dL. First-day vasopressorsand corticosteroids were also associated with higher mortality; insulinexposure marked higher risk after adjustment.
CONCLUSIONS AND RELEVANCE: During the first ICU day, exposure-aware TWAG assessment identified a practical upper boundary near 140 mg/dL associated with higher 28-day mortality. An interpretable ensemble integrating TWAG, treatments, and physiology provided accurate first-day risk estimates, supporting risk-informed, individualized glycemic targets and earlier intervention in high-risk ICU patients.
OBJECTIVE: To examine the association between first-day time-weighted average glucose (TWAG) and 28-day mortality, and to evaluate GlucoSurvAI, an interpretable ensemble model for first-day risk stratification.
DESIGN SETTING AND PARTICIPANTS: Retrospective cohort study using electornic health records from 13 U.S. hospitals. Among 18,868 adult ICU encounters, 8,048 patients from 7 U.S. hospitals met inclusion criteria (≥1 glucose value and hospital length of stay ≥24 hours).
EXPOSURES: First-day glycemic exposure summarized as TWAG, categorized as <100, 100-139 (reference), 140-179, and ≥180 mg/dL. Prespecified covariates included diabetes/prediabetes, first-day insulin and glucose, corticosteroids, vasopressors, shock, cancer, glucose-monitoring intensity, and clinical site.
MAIN OUTCOME AND MEASURES: Primary outcome: 28-day all-cause mortality. Associations were estimated with multivariable Cox models (adjusted hazard ratios [aHRs], 95% CIs). GlucoSurvAI performance was assessed using Area Under the Receiver Operating Characteristic (AUROC) and Brier score; SHapley Additive exPlanations (SHAP) provided 28-day interpretability.
RESULTS: Of 8,048 patients, most were euglycemic (70-180 mg/dL) on day 1, although hyperglycemic excursions were frequent. Higher TWAG was associated with higher 28-day mortality: 140-179 mg/dL aHR 1.42 (95% CI, 1.25-1.62); ≥180 mg/dL aHR 1.41 (95% CI, 1.17-1.69). TWAG <100 mg/dL showed a nonsignificant trend toward higher survival. GlucoSurvAI achieved AUROC 0.967 (±0.008) with a low Brier score (~0.026). Adjusted SHAP analyses paralleled Cox results, identifying 100-139 mg/dLas the exposure range associated with decreased mortality, with risk increasing ≥140 mg/dL. First-day vasopressorsand corticosteroids were also associated with higher mortality; insulinexposure marked higher risk after adjustment.
CONCLUSIONS AND RELEVANCE: During the first ICU day, exposure-aware TWAG assessment identified a practical upper boundary near 140 mg/dL associated with higher 28-day mortality. An interpretable ensemble integrating TWAG, treatments, and physiology provided accurate first-day risk estimates, supporting risk-informed, individualized glycemic targets and earlier intervention in high-risk ICU patients.